Law Offices of Howard G. Smith LLP Continues Investigation of Pharmaceutical Product Development, Inc.

Law Offices of Howard G. Smith is continuing its investigation of potential claims against the Board of Directors of Pharmaceutical Product Development, Inc. (“PPD” or the “Company”) (NASDAQ:PPDI) related to the proposed acquisition of the Company to an affiliate of The Carlyle Group and Hellman & Friedman. The transaction is valued at approximately $3.9 billion or $33.25 per share and is expected to close by the end of fourth quarter 2011.

The investigation concerns whether the Board of Directors of PPD breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Its share price skyrocketed from $24.70 on August 8, 2011 to $32.28 on August 18, 2011. Further, at least one analyst has set a target price for the Company’s stock at $38.00.

If you are a shareholder of PPD, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], Toll Free at [phone], or by email to [e-mail], or visit our website at http://www.howardsmithlaw.com.